![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (S)-nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of F2RL2 mRNA | CTD | PMID:27782041 | 1,2-dimethylhydrazine | decreases expression | ISO | F2rl2 (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of F2RL2 mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of F2RL2 mRNA | CTD | PMID:32109520 | 3,3',5,5'-tetrabromobisphenol A | increases expression | ISO | F2rl2 (Mus musculus) | 6480464 | tetrabromobisphenol A results in increased expression of F2RL2 mRNA | CTD | PMID:25172293 | 8-Br-cAMP | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | 8-Bromo Cyclic Adenosine Monophosphate results in increased expression of F2RL2 mRNA | CTD | PMID:20147733 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of F2RL2 mRNA | CTD | PMID:31881176 | acetamiprid | increases expression | EXP | | 6480464 | acetamiprid results in increased expression of F2RL2 mRNA | CTD | PMID:27782041 | aflatoxin B1 | increases methylation | ISO | F2RL2 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased methylation of F2RL2 gene | CTD | PMID:27153756 | aflatoxin B1 | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of F2RL2 mRNA | CTD | PMID:32234424 | all-trans-retinoic acid | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Tretinoin results in increased expression of F2RL2 mRNA | CTD | PMID:21934132 | ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of F2RL2 mRNA | CTD | PMID:16483693 | atrazine | decreases expression | EXP | | 6480464 | Atrazine results in decreased expression of F2RL2 mRNA | CTD | PMID:36841081 | benzo[a]pyrene | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased expression of F2RL2 mRNA | CTD | PMID:20064835 and PMID:32234424 | benzo[a]pyrene | increases methylation | ISO | F2RL2 (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of F2RL2 promoter | CTD | PMID:27901495 | bis(2-ethylhexyl) phthalate | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Diethylhexyl Phthalate results in decreased expression of F2RL2 mRNA | CTD | PMID:31163220 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of F2RL2 mRNA | CTD | PMID:25181051 | bisphenol A | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | bisphenol A results in increased expression of F2RL2 mRNA | CTD | PMID:29275510 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of F2RL2 gene | CTD | PMID:28505145 | C60 fullerene | decreases expression | EXP | | 6480464 | fullerene C60 results in decreased expression of F2RL2 mRNA | CTD | PMID:19167457 | cadmium atom | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of F2RL2 mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of F2RL2 mRNA | CTD | PMID:35301059 | calcitriol | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Calcitriol results in decreased expression of F2RL2 mRNA | CTD | PMID:26485663 | CGP 52608 | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to F2RL2 gene] | CTD | PMID:28238834 | cisplatin | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Cisplatin results in increased expression of F2RL2 mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of F2RL2 mRNA | CTD | PMID:27392435 | cyclophosphamide | increases expression | EXP | | 6480464 | Cyclophosphamide results in increased expression of F2RL2 protein | CTD | PMID:15643279 | cyclosporin A | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Cyclosporine results in increased expression of F2RL2 mRNA | CTD | PMID:20106945 | dioxygen | multiple interactions | EXP | | 6480464 | [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of F2RL2 mRNA | CTD | PMID:33729688 | disodium selenite | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Sodium Selenite results in increased expression of F2RL2 mRNA | CTD | PMID:24383545 | dorsomorphin | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Doxorubicin results in decreased expression of F2RL2 mRNA | CTD | PMID:29803840 | entinostat | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | entinostat results in decreased expression of F2RL2 mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA | CTD | PMID:27188386 | flavonoids | decreases expression | EXP | | 6480464 | Flavonoids results in decreased expression of F2RL2 mRNA | CTD | PMID:18035473 | imidacloprid | increases expression | EXP | | 6480464 | imidacloprid results in increased expression of F2RL2 mRNA | CTD | PMID:27782041 | lead diacetate | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | lead acetate results in increased expression of F2RL2 mRNA | CTD | PMID:27562236 | lipopolysaccharide | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of F2RL2 mRNA | CTD | PMID:35811015 | mercury dibromide | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | mercuric bromide results in increased expression of F2RL2 mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA | CTD | PMID:27188386 | methylisothiazolinone | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | 2-methyl-4-isothiazolin-3-one results in decreased expression of F2RL2 mRNA | CTD | PMID:31629900 | methylmercury chloride | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of F2RL2 mRNA | CTD | PMID:28001369 | methylmercury chloride | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | methylmercuric chloride results in increased expression of F2RL2 mRNA | CTD | PMID:28001369 | nickel sulfate | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | nickel sulfate results in decreased expression of F2RL2 mRNA | CTD | PMID:22714537 | nicotine | increases expression | EXP | | 6480464 | Nicotine results in increased expression of F2RL2 mRNA | CTD | PMID:27782041 | O-methyleugenol | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | methyleugenol results in increased expression of F2RL2 mRNA | CTD | PMID:32234424 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of F2RL2 mRNA | CTD | PMID:25729387 | p-chloromercuribenzoic acid | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in increased expression of F2RL2 mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA | CTD | PMID:27188386 | panobinostat | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA | CTD | PMID:27188386 | panobinostat | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | panobinostat results in decreased expression of F2RL2 mRNA | CTD | PMID:26272509 | paracetamol | affects expression | ISO | F2rl2 (Mus musculus) | 6480464 | Acetaminophen affects the expression of F2RL2 mRNA | CTD | PMID:17562736 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of F2RL2 mRNA | CTD | PMID:30723492 | perfluorooctanoic acid | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | perfluorooctanoic acid results in increased expression of F2RL2 mRNA | CTD | PMID:36251517 | phenethyl isothiocyanate | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | phenethyl isothiocyanate results in increased expression of F2RL2 mRNA | CTD | PMID:26678675 | phenformin | decreases expression | EXP | | 6480464 | Phenformin results in decreased expression of F2RL2 mRNA | CTD | PMID:31324951 | phenylmercury acetate | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in increased expression of F2RL2 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL2 mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | ISO | F2rl2 (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of F2RL2 mRNA | CTD | PMID:17950772 | pirinixic acid | multiple interactions | ISO | F2rl2 (Mus musculus) | 6480464 | NCF1 protein promotes the reaction [pirinixic acid results in decreased expression of F2RL2 mRNA] and PPARA protein promotes the reaction [pirinixic acid results in decreased expression of F2RL2 mRNA] | CTD | PMID:17950772 | progesterone | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Progesterone results in decreased expression of F2RL2 mRNA | CTD | PMID:20864642 | quercitrin | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | quercitrin results in decreased expression of F2RL2 mRNA | CTD | PMID:25193878 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine co-treated with Lipopolysaccharides] results in increased expression of F2RL2 mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Silicon Dioxide analog results in increased expression of F2RL2 mRNA | CTD | PMID:23806026 | sodium arsenite | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of F2RL2 mRNA | CTD | PMID:22714537 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of F2RL2 mRNA | CTD | PMID:34492290 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in increased expression of F2RL2 mRNA | CTD | PMID:25729387 | topotecan | increases expression | EXP | | 6480464 | Topotecan results in increased expression of F2RL2 mRNA | CTD | PMID:25729387 | trichloroethene | increases methylation | EXP | | 6480464 | Trichloroethylene results in increased methylation of F2RL2 gene | CTD | PMID:27618143 | trichloroethene | decreases expression | EXP | | 6480464 | Trichloroethylene results in decreased expression of F2RL2 mRNA | CTD | PMID:33387578 | trichostatin A | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of F2RL2 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA | CTD | PMID:27188386 | triclosan | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Triclosan results in decreased expression of F2RL2 mRNA | CTD | PMID:30510588 | valproic acid | increases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of F2RL2 mRNA | CTD | PMID:23179753 and PMID:28001369 | valproic acid | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of F2RL2 mRNA | CTD | PMID:23179753 more ... | valproic acid | affects expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Valproic Acid affects the expression of F2RL2 mRNA | CTD | PMID:25979313 | valproic acid | decreases methylation | ISO | F2RL2 (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of F2RL2 gene | CTD | PMID:29154799 | vorinostat | multiple interactions | ISO | F2RL2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of F2RL2 mRNA | CTD | PMID:27188386 | vorinostat | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | vorinostat results in decreased expression of F2RL2 mRNA | CTD | PMID:26272509 | zinc atom | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Zinc results in decreased expression of F2RL2 mRNA | CTD | PMID:16870260 | zinc dichloride | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | zinc chloride results in decreased expression of F2RL2 mRNA | CTD | PMID:16870260 | zinc(0) | decreases expression | ISO | F2RL2 (Homo sapiens) | 6480464 | Zinc results in decreased expression of F2RL2 mRNA | CTD | PMID:16870260 | |